Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2009-012499-28-IT
EUCTR2009-012499-28-IT
Active, not recruiting
Not Applicable

Efficacy of the treatment with hydroxychloroquine in non responders HIV-infected HAART-treated patients - ND

AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)0 sites40 target enrollmentAugust 11, 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHIV infection (immunological nonresponders).MedDRA version: 9.1Level: LLTClassification code 10008922

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
HIV infection (immunological nonresponders).
Sponsor
AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
Enrollment
40
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 11, 2009
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)

Eligibility Criteria

Inclusion Criteria

  • •18 years of age or older patients, HIV positive with CD4 nadir pre\-HAART\<100cell/mm3, that meet the definition of INR, with an absolute T CD4\+ count less than 200cells/mm3 and an increase in T CD4\+ count less than 5% in the previous 6 months despite an effective antiretroviral therapy with NNRTI or bPI \+2 NRTI.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •Chronic liver disease, cardiopathy, retinopathy, known hypersensitivity to chloroquine and hydroxychloroquine, G6PDH deficit and pregnant and/or nursing women.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic HIV-infected patients (HCQ-01) - Hydroxychloroquine studyHIV infectionMedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infection
EUCTR2007-005057-36-GBMedical Research Council
Completed
Not Applicable
HCQ-01 Trial: evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic human immunodeficiency virus (HIV) infected patients
ISRCTN30019040Medical Research Council Clinical Trials Unit (MRC CTU) (UK)90
Not yet recruiting
Phase 3
Efficacy of hydroxychloroquine in graves disease in addition to antithyroid drugs.Health Condition 1: E050- Thyrotoxicosis with diffuse goiter
CTRI/2023/07/054894IPQA laboratories
Recruiting
Phase 3
Hydroxychloroquine in comparison with hydroxychloroquine + azithromycin in patients with covid-19COVID-19.U07.1 - COVID-19COVID-19
IRCT20200428047228N2Quality Improvement of Intensive Care Research Center- Shahid Beheshti University40
Recruiting
Not Applicable
Evaluate the efficacy of hydroxychloroquine in the prevention of SARS-COV2 infection in high risk health care workers
IRCT20200414047076N1Esfahan University of Medical Sciences160